Application of 3D printing technology in transcatheter aortic valve replacement for bicuspid aortic stenosis
10.12007/j.issn.0258-4646.2025.10.014
- VernacularTitle:3D打印技术在经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄中的应用
- Author:
Hang ZHANG
1
;
Huajun WANG
1
;
Fengwu SHI
1
;
Su LIU
1
;
Qianli MA
1
;
Jinghui AN
1
Author Information
1. 河北医科大学第二医院心脏外科,石家庄 050061
- Publication Type:Journal Article
- Keywords:
3D printing;
transcatheter aortic valve replacement;
bicuspid aortic stenosis
- From:
Journal of China Medical University
2025;54(10):942-945,957
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of 3D printing technology in transcatheter aortic valve replacement(TAVR)for bicuspid aortic stenosis.Methods We retrospectively analyzed the clinical data of patients who underwent TAVR for bicuspid aortic stenosis at the Department of Cardiac Surgery of the Second Hospital of Hebei Medical University between January 2020 and January 2023.Seven-ty patients were divided into 3D printing and non-3D printing groups of 35 each,based on whether or not 3D printing technology was applied,and the perioperative clinical data of the two groups were compared.Results The patients' postoperative symptoms signifi-cantly improved compared with those before the operation,and the left ventricular ejection fraction increased to varying degrees.Compared with the non-3D printing group,the operation time,X-ray irradiation time.and transvalvular time in the 3D printing group were signifi-cantly shortened,and the probabilities of the occurrence of postoperative"flap-to-flap"implantation and conduction block were signifi-cantly reduced,with statistically significant differences(P＜0.05).There was no statistically significant difference(P＞0.05)in the inci-dence of moderate and above perivalvular leakage,valve displacement,or conversion to thoracotomy between the two groups after surgery.Conclusion 3D printing technology can effectively guide the TAVR treatment of bicuspid aortic stenosis.While significantly shortening the operation time,it can effectively increase the success rate of TAVR and reduce the risk of adverse events,providing a new approach for the transcatheter treatment of bicuspid aortic stenosis.
